Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (January 2023)
26 slides from Century Therapeutics's investor presentation, Jan 9, 2023
Slide 1: Corporate Overview January 2023
Corporate OverviewJanuary 2023
Slide 2: Forward-looking statements
2 Forward-looking statementsThis presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or
Slide 3: Investment Thesis
3 Investment Thesis Next generation platforms for iNKand gamma delta iTcandidates Foundational investments in iPSC technology, genetic editing, and manufacturing Experienced team in R&D, immuno-oncology, manufacturing and commercializationExemplified by FDA clearance of Century’s first IND for CNTY-
Slide 4: Finding operational efficiencies to extend the cash runway
4 Finding operational efficiencies to extend the cash runwayPortfolio Prioritization Operational efficiencies•Prioritization of key pipeline assets enabled by de-prioritizing further investment in CNTY-103•CNTY-107 (Nectin-4+ tumors), CNTY-102 (lymphomas) have BIC potential•Not overinvesting in any
Slide 5: Century Therapeutics
CENTURY THERAPEUTICS
Slide 6: Building a next generation allogeneic cell therapy platform
6 Building a next generation allogeneic cell therapy platform Gene Editing•Proprietary gene editing platform•CRISPR MAD7-derived gene editing for precise transgene integrationProtein Engineering•Developing proprietary next-generation CARs•Universal tumor targeting platformiPSC Differentiation/Manufa
Slide 7: Foundational investments in iPSC know-how and manufacturing
7 Foundational investments in iPSC know-how and manufacturing Established in-house manufacturing accelerates learnings and enables faster product iteration•53,000 ft2facility •Designed to produce multiple immune cell types•Two sites provides optionality and maximizes flexibilityiPSC license and coll
Slide 8: Precision CRISPR MAD7 mediated sequential gene editing of iPSC
8 Multiple gene edits (KO/KI)iPSC bank Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates Engineered iPSC Master Cell Bank(MCB) Advantages of Century’s PlatformPreciseCRISPR mediated homology directed repair reduces off-target integrationStepwis
Slide 9: Potential to drive durable responses with engineering to resist immune rejection
9 Potential to drive durable responses with engineering to resist immune rejectionAllo-EvasionTMedits + repeat dosing = potential greater durability Next-wave of allogeneic cell therapies must solve for challenge of rejection
Slide 10: Allo-Evasion 1.0 designed to overcome host vs graft rejection
10 Allo-EvasionTM1.0 designed to overcome 3 major pathways of host vs graft rejection1.Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells 2.Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells3.Knock-in of HLA-
Slide 11: Allo-Evasion 3.0 Provides Additional Protection Against NK Cell Killing
11 Allo-EvasionTM3.0 Provides Additional Protection Against NK Cell Killing1.Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells 2.Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells3.Knock-in of HLA-E prevents
Slide 12: Expression of HLA-E + HLA-G further protects from NK cell killing
12 Expression of HLA-E + HLA-G further protects from NK cell killing HLA-EHLA-GNKG2AKIRs, LIRsActivating ligandActivating receptorProof-of-Concept Study with HLA-I Null K562 Cells Engineered with HLA-E and HLA-G 0.1250.250.512481632 02040 60 80100 Donor RC01Ratio (E:T)% KillingParental K562 HLA-G K5
Slide 13: Century Therapeutics
CENTURY THERAPEUTICS
Slide 14: Common progenitor milestone enables cost, time efficiencies
14 Common progenitor milestone enables cost, time efficiencies Multiple gene editsEngineered iPSC iNK celliPSC bank Cell engineeringManufacturingCommon ProgenitoriNK3.0 CD34+HSC T cell Reprogramming Reprogramming DifferentiationNK cell •iPSC cell bank with 12 core 3.0 gene edits introduced in 5 sequ
Slide 15: iNK common progenitor edits confer improved persistence and anti-tumor efficacy
15 iNKcommon progenitor edits confer improved persistence and anti-tumor efficacy Engineering with IL15/IL15Ra shows increased persistence in vitro and in vivoHigh affinity CD16 demonstrates enhanced ADCC activityGurung, et al, SITC 2022 iNKcells engineered with NKG2D demonstrate enhanced tumor cell
Slide 16: Pipeline and Franchises
Pipeline and Franchises
Slide 17: Updated pipeline
17 ProductiPSC PlatformTargetsIndicationsDiscoveryPreclinicalClinicalCollaboratorCNTY-101iNKCD19B-Cell MalignanciesCNTY-102iT CD19 + CD79bB-Cell MalignanciesCNTY-107iTNectin-4Solid TumorsPrograms in Collaboration CNTY-104iNK/iTMulti-specificAcute Myeloid LeukemiaCNTY-106iNK/iTMulti-specificMultiple
Slide 18: Promise of allogeneic cell therapies in lymphoma intact
18 Promise of allogeneic cell therapies in lymphoma intact Large unmet need remains despite progress with autologous cell therapies•~25% of eligible patients receive CAR-T therapy1•~35% of patients achieve long- term remission even in earlier lines of therapy1Off-the-shelf modalities approaching bar
Slide 19: CNTY-101: Differentiated next-gen CD19 targeted product
19 Differentiating features:First cell therapy product candidate designed to avoid all major pathways of host vs graft rejection to realize potential of repeat dosingPotential to exceed bar set by autologous and deliver durable responses Vision to eliminate need for lymphodepletion with subsequent c
Slide 20: CNTY-101 shows strong pre-clinical anti-tumor activity
20 CNTY-101 shows strong pre-clinical anti-tumor activity In Vitro Serial killing assay Robust activity against lymphoma xenograftBorges, et al, ASH2021
Slide 21: ELiPSE-1: First-in-Human Study CNTY-101
21 ELiPSE-1: First-in-Human Study CNTY-101Study will assess:Impact of Allo-EvasionTMon iNK cell persistence and PK after multiple dosing (Schedule B)Multiple dose regimen with up to 6 doses with single lymphodepletion conditioningPotential to increase durability of responses with Allo-EvasionTMenabl
Slide 22: Winning in Solid Tumors
22 Winning in Solid Tumors Trafficking and infiltration γδiTcells -tissue homing TME / Immunosuppressive environment Requirement for chemotherapy conditioning Tumor heterogeneity •Novel conditioning regimens•Genetic engineeringChallengesCentury’s Solution Future engineering strategies •Engage endoge
Slide 23: iPSC-derived GD T cells effective at tumor control
23 iPSC-derived GD T cells effective at tumor control as monotherapy and in combination with antibody Millar, et al, SITC 2022γδ-EGFR-CAR-T cells demonstrate significant CAR killing of ovarian spheroids γδCAR-T demonstrate additive efficacy in combination with trastuzumab Treatment% TGISignificance
Slide 24: CNTY-107: First in Class Nectin-4 Targeted GD iT Cell Therapy
24 CNTY-107: First in Class Nectin-4 Targeted GD iTCell TherapyNectin-4 has been validated by ADC approaches•Opportunity to address multiple Nectin-4 positive solid tumors•Potential indications include bladder, breast, pancreatic, non-small cell lung cancer, esophageal/gastric, head and neck, and/or
Slide 25: Strategy and 3-year vision for growth
25 Strategy and 3-year vision for growthDelivering on potential for allogeneic cell therapies by exceeding efficacy, safety and logistics of autologous approaches2026+Advancing multiple development candidatesClinical trial execution (ELiPSE-1) CNTY-102 development candidate pre-clinical data Multipl
Slide 26: Emerging leader in cell therapies for cancer
Emerging leader in cell therapies for cancerComprehensive iPSC cell platformFor immune effector cellsTechnical ExpertiseGenetic and protein engineering, process development and immuno-oncologyFoundation in ScienceContinuing investment in innovation drives R&DState-of-the-art GMP manufacturing facili
Century Therapeutics — Investor Presentation (January 2023) on 6ix